Suppr超能文献

男孩体质性生长和青春期延迟的口服治疗:一项合成代谢类固醇或十一酸睾酮的随机试验

Oral treatment for constitutional delay of growth and puberty in boys: a randomised trial of an anabolic steroid or testosterone undecanoate.

作者信息

Albanese A, Kewley G D, Long A, Pearl K N, Robins D G, Stanhope R

机构信息

Medical Unit, Institute of Child Health, London.

出版信息

Arch Dis Child. 1994 Oct;71(4):315-7. doi: 10.1136/adc.71.4.315.

Abstract

Thirty three boys (mean 14.6 years old, range 12.8-16.2 years) with constitutional delay of growth and puberty were randomised into two groups to determine which form of oral treatment would give the better anthropometric response. The two drugs were administered by mouth (one tablet/day) for a mean of 3.5 months (range 3-7 months). At randomisation, 17 boys received testosterone undecanoate (40 mg/day) and 16 oxandrolone (2.5 mg/day). At the start of treatment they were prepubertal or in early puberty, their height SD score was -1.97 in boys treated with testosterone and -2.21 in those treated with oxandrolone, and their growth rates were 4.3 and 4.2 cm/year respectively. Both sex steroid and anabolic steroid treatments induced a significant growth acceleration in all patients except four (three treated with testosterone and one with oxandrolone). When treated with the alternative sex steroid, all four non-responders had a significant anthropometric response. In all boys the induced growth acceleration was sustained when treatment was interrupted. There was no significant difference in the induced growth spurt and bone maturation between the two groups. Spontaneous progress into puberty was achieved in all boys with an increase in testicular volume from a mean of 4.6 to 8.5 ml. The rate of development in secondary sexual characteristics was also similar in the two groups. These data suggest that oral testosterone and oxandrolone are equally effective in the treatment of growth delay in boys with constitutional delay of growth and puberty.

摘要

33名患有体质性生长和青春期延迟的男孩(平均年龄14.6岁,范围12.8 - 16.2岁)被随机分为两组,以确定哪种口服治疗方式能带来更好的人体测量学反应。两种药物均口服(每日1片),平均服用3.5个月(范围3 - 7个月)。随机分组时,17名男孩接受十一酸睾酮(40毫克/天)治疗,16名接受氧雄龙(2.5毫克/天)治疗。治疗开始时,他们处于青春期前或青春期早期,接受睾酮治疗的男孩身高标准差分数为 -1.97,接受氧雄龙治疗的为 -2.21,他们的生长速率分别为4.3厘米/年和4.2厘米/年。除4名患者(3名接受睾酮治疗,1名接受氧雄龙治疗)外,性类固醇和合成代谢类固醇治疗均使所有患者出现显著的生长加速。当用另一种性类固醇治疗时,所有4名无反应者均出现显著的人体测量学反应。在所有男孩中,治疗中断后诱导的生长加速得以持续。两组之间诱导的生长突增和骨骼成熟度无显著差异。所有男孩睾丸体积从平均4.6毫升增加到8.5毫升,均自然进入青春期。两组第二性征的发育速率也相似。这些数据表明,口服睾酮和氧雄龙在治疗患有体质性生长和青春期延迟的男孩生长延迟方面同样有效。

相似文献

引用本文的文献

1
Puberty Induction in Adolescent Males: Current Practice.青春期男性的青春期诱导:当前实践
Cureus. 2022 Apr 5;14(4):e23864. doi: 10.7759/cureus.23864. eCollection 2022 Apr.
2
Recent advancement in the treatment of boys and adolescents with hypogonadism.性腺功能减退男孩和青少年治疗的最新进展。
Ther Adv Endocrinol Metab. 2022 Jan 5;13:20420188211065660. doi: 10.1177/20420188211065660. eCollection 2022.
3
Testosterone Use in Adolescent Males: Current Practice and Unmet Needs.青少年男性使用睾酮:当前实践与未满足的需求
J Endocr Soc. 2020 Oct 30;5(1):bvaa161. doi: 10.1210/jendso/bvaa161. eCollection 2021 Jan 1.
4
Androgen Treatment in Adolescent Males With Hypogonadism.雄激素治疗青春期性腺功能减退症男性。
Am J Mens Health. 2020 May-Jun;14(3):1557988320922443. doi: 10.1177/1557988320922443.
7
8
A new oral testosterone undecanoate formulation.一种新型口服十一酸睾酮制剂。
World J Urol. 2003 Nov;21(5):311-5. doi: 10.1007/s00345-003-0372-x. Epub 2003 Oct 25.

本文引用的文献

2
Variations in the pattern of pubertal changes in boys.男孩青春期变化模式的差异。
Arch Dis Child. 1970 Feb;45(239):13-23. doi: 10.1136/adc.45.239.13.
3
Effects of testosterone therapy for pubertal delay.睾酮治疗青春期延迟的效果。
Am J Dis Child. 1988 Jan;142(1):96-9. doi: 10.1001/archpedi.1988.02150010106035.
7
Delayed adolescence.青春期延迟
Clin Endocrinol Metab. 1975 Mar;4(1):143-55. doi: 10.1016/s0300-595x(75)80037-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验